0001551986-20-000222.txt : 20200708
0001551986-20-000222.hdr.sgml : 20200708
20200708162951
ACCESSION NUMBER: 0001551986-20-000222
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200706
FILED AS OF DATE: 20200708
DATE AS OF CHANGE: 20200708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sitar Edward J
CENTRAL INDEX KEY: 0001603489
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
FILM NUMBER: 201018660
MAIL ADDRESS:
STREET 1: 39 FLAMING ARROW ROAD
CITY: MAHWAH
STATE: NJ
ZIP: 07430
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273948465
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
4
1
wf-form4_159424017643845.xml
FORM 4
X0306
4
2020-07-06
0
0001551986
9 METERS BIOPHARMA, INC.
NMTR
0001603489
Sitar Edward J
C/O 9 METERS BIOPHARMA, INC.
8480 HONEYCUTT RD, STE 120
RALEIGH
NC
27615
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
0.6216
2020-07-06
4
A
0
550000
0
A
2030-07-06
Common stock
550000.0
550000
D
Stock Option (Right to Buy)
0.6216
2020-07-06
4
A
0
225000
0
A
2030-07-06
Common stock
225000.0
775000
D
25% of these shares shall be deemed vested and exercisable on July 6, 2021 with the remainder vesting in equal monthly installments over the next 36 months, such that the option shall be fully vested on the fourth anniversary of the grant date, subject to the executive's continued service with the Company through each applicable vesting date.
The option vest, if at all, upon satisfaction of certain performance criteria as determined by the Board in its discretion. Vesting will begin on the date the Board deems the performance criteria met (the "Performance Date"). Each performance tranche, consisting of 112,500 shares subject to the option, shall vest 25% on the one-year anniversary of the Performance Date with the remainder vesting monthly over 36 months following the Performance Date.
/s/ Edward J. Sitar
2020-07-08